

**REMARKS**

Applicant requests entry of the amendment and reconsideration based on the accompanying remarks. Claims 1-3, 5, and 42-43 are currently pending in this application. Claims 4, 6-41 and 44-46 are cancelled. No new matter has been added.

**A. INFORMALITIES**

The Examiner has objected to the disclosure because of a number of informalities. Specifically, two occurrences of “http://” and underlining resulting in active imbedded hyperlinks on page 23. The amendment to the specification deletes the occurrences of “http://”, the underlining, and imbedded hyperlinks thereby correcting the informalities noted by the Examiner.

**B. 35 U.S.C. §112, FIRST PARAGRAPH**

The Examiner has rejected claims 1-3, 5, 6, 12-14 and 42-46 because Applicant is not in compliance with Deposit rule 37 C.F.R. §1.809(d) and for failing to provide an acceptable statement of corroboration under MPEP 2406.02

Applicant has amended the 37 C.F.R. §1.809(d) statement on page 56 of the specification to include the patent deposit designation number PTA-6133 and the date the biological material was deposited with ATCC in Manassas, Virginia. Applicant also provides a statement of corroboration under MPEP 2406.02 wherein the Assignee of the invention attests that the biological material deposited with the ATCC on July 30, 2004 is identical to the biological material identified in the application as originally filed as the hybridoma designated “KKO”. A copy of the 37 C.F.R. 3.73(b) (PTO/SB96) statement by the Assignee, filed on March 23, 2004, is provided for the Examiner’s convenience.

Applicant respectfully submits that the amendment to the specification and the statement of corroboration place the application in condition for allowance.

**C. CONCLUSION**

For the above reasons, Applicant respectfully submits that the application is in condition for allowance with claims 1-3, 5, and 42-43. If there remain any issues that may be disposed of via a telephonic interview, the Examiner is kindly invited to contact the undersigned at the number given below. The Director of the Patent and Trademark Office is authorized to charge any necessary fees, and conversely, deposit any credit balance, to Deposit Account No. 18-1579.

Respectfully submitted,

ROBERTS ABOKHAIR & MARDULA, LLC



Janeen VILVEN

Reg. No. 47156

11800 Sunrise Valley Drive

Suite 1000

Reston Virginia 20191

(505) 922-1400



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
AREPALLY *et al.*

Atty. Docket No.: 2687-021/MC-166

Appln. No.: 09/615,872

Group Art Unit: 1641

Filed: July 13, 2000  
Conf. No.: 4363

Examiner: James GRUN

Title: COMPOSITIONS AND METHODS  
USEFUL FOR THE DIAGNOSIS AND  
TREATMENT OF HEPARIN INDUCED  
THROMBOCYTOPENIA/THROMBOSIS

**Corroboration Statement under MPEP 2406.02**

The undersigned is the Assignee of the above identified application. The undersigned does hereby attest that the biological material deposited with the American Type Culture Collection (ATCC) on July 30, 2004 and identified by the ATCC Patent Depository Designation number PTA-6133, is identical to the hybridoma designated "KKO" in the 09/615,872 specification as filed on July 13, 2000.

Respectfully submitted,

Elizabeth J. Kuuttila  
President and CEO  
Science and Technology@UNM